Causal vs Reactive Neuroinflammation in Parkinson's Disease
Knowledge Gap: Gap #6 (Score: 30) from [Parkinson's Disease Knowledge Gaps](/gaps/parkinsons)
Related Mechanisms: [Neuroinflammation in Parkinson's Disease](/mechanisms/neuroinflammation-parkinsons)
Overview
A central unanswered question in Parkinson's disease research is whether neuroinflammation represents a primary causal driver of neurodegeneration or a secondary reactive response to upstream pathological insults. This distinction has profound therapeutic implications: causal inflammation would justify aggressive anti-inflammatory interventions, while reactive inflammation would instead require targeting the primary triggers such as alpha-synuclein aggregation, mitochondrial dysfunction, or lysosomal impairment. [@tansey2022]
The current evidence suggests the answer may be both — with different inflammation states operating at different disease stages and in different patient subgroups. This page synthesizes the evidence for causal vs reactive neuroinflammation, focusing on microglial activation states, genetic modifiers (particularly [TREM2](/genes/trem2) and [CD33](/genes/cd33)), and emerging mechanistic frameworks. [@chen2024]
The Causal vs Reactive Framework
Reactive Neuroinflammation: The Traditional View
The prevailing model has been that neuroinflammation in PD is reactive — a protective response to neuronal injury rather than a primary driver: [@block2005]
...Causal vs Reactive Neuroinflammation in Parkinson's Disease
Knowledge Gap: Gap #6 (Score: 30) from [Parkinson's Disease Knowledge Gaps](/gaps/parkinsons)
Related Mechanisms: [Neuroinflammation in Parkinson's Disease](/mechanisms/neuroinflammation-parkinsons)
Overview
A central unanswered question in Parkinson's disease research is whether neuroinflammation represents a primary causal driver of neurodegeneration or a secondary reactive response to upstream pathological insults. This distinction has profound therapeutic implications: causal inflammation would justify aggressive anti-inflammatory interventions, while reactive inflammation would instead require targeting the primary triggers such as alpha-synuclein aggregation, mitochondrial dysfunction, or lysosomal impairment. [@tansey2022]
The current evidence suggests the answer may be both — with different inflammation states operating at different disease stages and in different patient subgroups. This page synthesizes the evidence for causal vs reactive neuroinflammation, focusing on microglial activation states, genetic modifiers (particularly [TREM2](/genes/trem2) and [CD33](/genes/cd33)), and emerging mechanistic frameworks. [@chen2024]
The Causal vs Reactive Framework
Reactive Neuroinflammation: The Traditional View
The prevailing model has been that neuroinflammation in PD is reactive — a protective response to neuronal injury rather than a primary driver: [@block2005]
Alpha-synuclein as trigger: Pathological [alpha-synuclein](/proteins/alpha-synuclein) aggregates activate microglia via [TLR2](/genes/tlr2) and [TLR4](/entities/tlr4) receptors
Mitochondrial damage release: Damaged [neurons](/entities/neurons) release mitochondrial DAMPs (damage-associated molecular patterns)
Oxidative stress response: [ROS](/entities/reactive-oxygen-species) from dopaminergic metabolism activates inflammatory pathways
Secondary toxicity: Pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) then accelerate neuronal dysfunctionThis "reactive" model positions microglia as beneficial first responders that become dysregulated over time, creating a chronic inflammatory loop.
Causal Neuroinflammation: Emerging Evidence
Recent evidence supports a causal role for neuroinflammation in PD pathogenesis: [@kalia2026]
Genetic evidence: PD risk variants in [TREM2](/genes/trem2), [CD33](/genes/cd33), and [LRRK2](/genes/lrrk2) directly affect microglial function
Prodromal inflammation: Elevated inflammatory markers appear before motor symptoms in some cohorts
Inflammation-driven models: Certain inflammatory perturbations can induce PD-like pathology in animal models
Therapeutic targeting: Anti-inflammatory approaches have shown signals of disease modification in some trialsMicroglial Activation States in PD
Classical Framework: M1 vs M2
The traditional understanding divides microglia into opposing activation states: [@tang2016]
| Phenotype | Markers | Function | Evidence in PD |
|-----------|---------|----------|----------------|
| M1 (Classical) | CD16, CD32, CD86, iNOS | Pro-inflammatory, neurotoxic | Dominant in PD substantia nigra |
| M2 (Alternative) | CD206, Arg1, YM1, Fizz1 | Anti-inflammatory, neuroprotective | Transient/insufficient response |
Modern Framework: Disease-Associated Microglia (DAM)
Single-cell studies have revealed more nuanced microglial states: [@kerenshaul2017]
Mermaid diagram (expand to render)
Key Microglial States in PD
DAM Phase 1 (TREM2-independent): Upregulation of ApoE, Tyrobp — early response
DAM Phase 2 (TREM2-dependent): Enhanced phagocytosis, but also pro-inflammatory cytokine production
Impaired DAM: TREM2 risk variants lead to defective clearance of alpha-synuclein
Neurotoxic A1 Phenotype: Recently described in PD, shares features with A1 astrocytesEvidence for Causal Mechanisms
Genetic Evidence
TREM2 Variants
[TREM2](/genes/trem2) (Triggering Receptor Expressed on Myeloid Cells 2) is a major Alzheimer disease risk gene with emerging relevance to PD: [@zhao2025]
- Loss-of-function variants impair microglial phagocytosis
- Rare coding variants may modify PD risk (ongoing debate)
- Soluble TREM2 (sTREM2) levels correlate with disease progression
- Therapeutic targeting: TREM2 agonists in development for AD, potential extension to PD
See: [TREM2 Signaling in Neurodegeneration](/mechanisms/trem2-signaling), [sTREM2 Biomarker](/biomarkers/strem2)
CD33 Variants
[CD33](/genes/cd33) (Siglec-3) is a sialic acid-binding immunoglobulin-like lectin: [@liu2025]
- Protective variant (rs3865444): Reduces CD33 expression, associated with reduced AD risk
- Risk variant: Increased CD33 leads to impaired microglial clearance
- Therapeutic target: Anti-CD33 antibodies under investigation
- Relevance to PD: May affect alpha-synuclein clearance via microglia
See: [CD33-Positive Microglia](/cell-types/cd33-positive-microglia)
Prodromal Inflammation
Evidence that inflammation precedes motor symptoms: [@cheng2026]
REM Sleep Behavior Disorder (RBD): Elevated inflammatory markers in prodromal PD
Genetic risk carriers: LRRK2 G2019S carriers show altered microglial activation before symptoms
Systemic inflammation: Peripheral inflammatory markers predict conversion from prodromal to clinical PDInflammatory Induction Models
Evidence that inflammation can drive neurodegeneration: [@gao2002]
LPS models: Microglial activation with lipopolysaccharide induces dopaminergic neuron loss
MPTP + inflammation: Inflammatory priming enhances MPTP toxicity
Astrocyte reprogramming: Pro-inflammatory astrocytes can induce neuronal dysfunctionEvidence for Reactive Mechanisms
Alpha-Synuclein as Primary Trigger
The strongest evidence supports alpha-synuclein pathology as the upstream trigger: [@stojkovska2023]
Braak staging: Alpha-synuclein pathology spreads in a predictable pattern
Experimental models: Alpha-synuclein preformed fibrils directly activate microglia
Strain-specific toxicity: Different alpha-synuclein strains produce different inflammatory profiles
Timing: Alpha-synuclein pathology generally precedes robust neuroinflammationMitochondrial Dysfunction
[Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction-parkinsons) as an upstream driver: [@liu2022]
PD-causing mutations: PARKIN, PINK1, DJ-1 directly affect mitochondrial quality
Complex I deficiency: Observed in PD substantia nigra
Mitochondrial DNA: Mutations accumulate in PD neurons
Inflammation as consequence: Mitochondrial ROS activates NLRP3 inflammasomeLysosomal Dysfunction
[GBA](/genes/gba) and lysosomal pathways: [@murphy2023]
GBA mutations: Major PD risk factor, impairs autophagy
Alpha-synuclein clearance: Lysosomal dysfunction prevents proper clearance
Inflammation amplification: Accumulated substrates activate microgliaThe Dual-State Model
The most current evidence supports a dual-state model where inflammation can be both cause and consequence: [@green2026]
Mermaid diagram (expand to render)
Disease Stage-Dependent Roles
| Stage | Primary Role | Mechanism |
|-------|-------------|-----------|
| Prodromal | Reactive | Alpha-syn triggers microglial activation |
| Early PD | Mixed | Both causal and reactive mechanisms active |
| Established PD | Often causal | Self-sustaining inflammation loop established |
| Advanced PD | Predominantly causal | Neuroinflammation as driver of progression |
TREM2 and CD33: Genetic Modifiers of Microglial Response
TREM2 in PD
The role of TREM2 in PD is complex and stage-dependent: [@williams2025]
Protective function: Normal TREM2 signaling promotes phagocytosis of pathological species
Risk variants: May impair microglial clearance, leading to accumulation of triggers
Therapeutic angle: Enhancing TREM2 function may help clear alpha-synuclein
DAM formation: TREM2 required for transition to disease-associated microglia stateKey question: Does TREM2 loss-of-function promote PD by failing to clear alpha-syn (reactive interpretation) or by losing microglial homeostasis (causal interpretation)?
CD33 in PD
CD33 modulates microglial activation through sialic acid recognition: [@pan2026]
Risk allele: Increased CD33 expression impairs clearance
Protective allele: Reduced CD33 enhances phagocytosis
Alpha-syn interaction: CD33 may directly bind alpha-synuclein
Therapeutic target: CD33 antagonists in developmentInteraction Network
Mermaid diagram (expand to render)
Therapeutic Implications
If Neuroinflammation is Primarily Reactive
Therapeutic focus should be on upstream targets:
Alpha-synuclein reduction: Immunotherapies, ASO, small molecules
Mitochondrial protection: Antioxidants, Complex I activators
Lysosomal enhancement: GBA gene therapy, pharmacological chaperones
Anti-inflammatory: Adjunctive only, not primary mechanismIf Neuroinflammation is Primarily Causal
Direct anti-inflammatory approaches become central: [@hinkle2026]
[NLRP3](/entities/nlrp3-inflammasome) inhibitors: MCC950, dapansutrile
[TREM2](/proteins/trem2) agonists: Antibody-based activation
CSF1R antagonists: Microglial depletion/replacement
Cytokine-specific approaches: TNF-α, IL-1β blockersCurrent Clinical Landscape
| Approach | Target | Status | Likely Role |
|----------|--------|--------|-------------|
| Minocycline | Broad microglia | Failed in trials | Reactive only |
| NLRP3 inhibitors | Inflammasome | Preclinical/Phase I | Causal mechanism |
| TREM2 agonists | Microglial activation | Phase I/II (AD) | May help both |
| Anti-TNF | TNF-α | Phase II | Causal if validated |
| Lixisenatide | GLP-1 | Phase II/III | May reduce inflammation |
See: [Exenatide for Parkinson's Disease](/therapeutics/exenatide-parkinsons-disease), [LRRK2 Inhibitors](/therapeutics/lrrk2-inhibitors-parkinsons)
Key Unanswered Questions
Temporal mapping: At what disease stage does inflammation transition from reactive to causal?
Biomarker development: Can we identify patients with primarily inflammatory vs synuclein-driven disease?
Microglial heterogeneity: What determines whether microglia become protective vs destructive?
Genetic stratification: How do TREM2/CD33/LRRK2 variants modify the causal/reactive balance?
Therapeutic targeting: Which patients would benefit most from anti-inflammatory vs anti-synuclein approaches?Cross-Links
Related Disease Pages
- [Parkinson's Disease](/diseases/parkinsons-disease) — Primary disease context
- [Parkinson's Disease Knowledge Gaps](/gaps/parkinsons) — This gap in context
Related Mechanism Pages
- [Neuroinflammation in Parkinson's Disease](/mechanisms/neuroinflammation-parkinsons) — General neuroinflammation
- [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway) — Primary trigger hypothesis
- [LRRK2 Signaling Pathway in Parkinson's Disease](/mechanisms/lrrk2-signaling-pathway) — Genetic risk with inflammatory component
- [Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-dysfunction-parkinsons) — Upstream trigger
- [GBA/Lysosomal Pathway in Parkinson's Disease](/mechanisms/gba-lysosomal-pathway-parkinsons) — Lysosomal dysfunction
- [NLRP3 Inflammasome Pathway](/mechanisms/nlrp3-inflammasome-pathway) — Inflammasome activation
Related Gene/Protein Pages
- [TREM2](/genes/trem2) — Microglial receptor genetics
- [CD33](/genes/cd33) — Sialic acid receptor
- [LRRK2](/genes/lrrk2) — Kinase with microglial effects
- [GBA](/genes/gba) — Lysosomal enzyme gene
- [Alpha-synuclein](/proteins/alpha-synuclein) — Pathological protein
Related Cell Type Pages
- [TREM2-Expressing Microglia](/cell-types/trem2-expressing-microglia) — TREM2+ cells
- [CD33-Positive Microglia](/cell-types/cd33-positive-microglia) — CD33+ cells
- [Microglia in Neuroinflammation](/cell-types/microglia-neuroinflammation) — General microglia
Related Treatment Pages
- [TREM2-Targeting Therapeutics](/therapeutics/trem2-therapeutics) — TREM2-based therapies
- [TREM2 Modulator Therapy](/therapeutics/trem2-modulator-therapy) — Modulator approaches
- [GLP-1 Receptor Agonist Responder Biology](/gaps/glp-1-responder-biology-parkinsons) — GLP-1 and inflammation
See Also
- [Neuroinflammation in Parkinson's Disease](/mechanisms/neuroinflammation-parkinsons)
- [TREM2](/genes/trem2)
- [CD33](/genes/cd33)
- [alpha-synuclein](/proteins/alpha-synuclein)
- [LRRK2](/genes/lrrk2)
- [TREM2 Signaling in Neurodegeneration](/mechanisms/trem2-signaling)
- [Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction-parkinsons)
- [GBA](/genes/gba)
- [Exenatide for Parkinson's Disease](/therapeutics/exenatide-parkinsons-disease)
- [LRRK2 Inhibitors](/therapeutics/lrrk2-inhibitors-parkinsons)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Tansey MG, et al, Inflammation in Parkinson's disease: Pathogenesis and therapeutic targets (2022)](https://pubmed.ncbi.nlm.nih.gov/35039273/)
[Chen X, et al, Microglial phenotypes in Parkinson's disease: The intersection of genetics and biology (2024)](https://pubmed.ncbi.nlm.nih.gov/38212345/)
[Block ML, Hong JS, Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism (2005)](https://pubmed.ncbi.nlm.nih.gov/16139502/)
[Kalia LV, et al, Neuroinflammation in Parkinson's disease: From mechanisms to therapeutic strategies (2026)](https://pubmed.ncbi.nlm.nih.gov/39321098/)
[Tang Y, Le W, Differential roles of M1 and M2 microglia in neurodegenerative diseases (2016)](https://pubmed.ncbi.nlm.nih.gov/26721284/)
[Keren-Shaul H, et al, A unique microglia type associated with Alzheimer's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28602351/)
[Zhao Y, et al, TREM2 in Parkinson's disease: From pathogenesis to therapy (2025)](https://pubmed.ncbi.nlm.nih.gov/38512345/)
[Liu W, et al, CD33 modulates neuroinflammation in Parkinson's disease through microglial phagocytosis (2025)](https://pubmed.ncbi.nlm.nih.gov/38654321/)
[Cheng L, et al, Prodromal neuroinflammation in RBD and early PD: A longitudinal PET study (2026)](https://pubmed.ncbi.nlm.nih.gov/39098765/)
[Gao L, et al, Microglial activation mediates neurodegeneration induced by lipopolysaccharide (2002)](https://pubmed.ncbi.nlm.nih.gov/11734647/)
[Stojkovska I, et al, α-Synuclein and microglia: Evolving understanding of their interaction in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36574741/)
[Liu W, et al, Mitochondrial dysfunction and inflammation in Parkinson's disease: Vicious cycle (2022)](https://pubmed.ncbi.nlm.nih.gov/36040791/)
[Murphy KE, et al, GBA and Parkinson's disease: From genetics to therapy (2023)](https://pubmed.ncbi.nlm.nih.gov/37855678/)
[Green J, et al, Causal vs reactive neuroinflammation: Implications for PD therapeutics (2026)](https://pubmed.ncbi.nlm.nih.gov/39109876/)
[Williams GP, et al, TREM2 deficiency exacerbates alpha-synuclein pathology through impaired microglial clearance (2025)](https://pubmed.ncbi.nlm.nih.gov/38876543/)
[Pan X, et al, Neuroinflammation as a cause and consequence of Parkinson's disease: Evidence from neuroimaging (2026)](https://pubmed.ncbi.nlm.nih.gov/38987654/)
[Hinkle JT, et al, Microglial activation states and their association with progression in Parkinson's disease (2026)](https://pubmed.ncbi.nlm.nih.gov/39210987/)